Over the last years, the biopharmaceutical industry has significantly turned its biologics
production towards mammalian cell expression systems. The presence of glycosylation …

As a key parameter impacting functional and structural heterogeneity, protein glycosylation
is a critical quality attribute for antibody biotherapeutic manufacturing. The glycan patterns …

Protein-based drugs constitute about a quarter of new approvals with a majority being
glycoproteins. Increasing use of glycoproteins, such as monoclonal antibodies, at high …

For several decades, glycoprotein biologics have been successfully produced from Chinese
hamster ovary (CHO) cells. The therapeutic efficacy and potency of glycoprotein biologics …

There are slightly over 165 recombinant pharmaceuticals currently approved for human use.
Another 500 protein candidates are in preclinical and clinical development, about 70% of …

The demand for production of glycoproteins from mammalian cell culture continues with an
increased number of approvals as biopharmaceuticals for the treatment of unmet medical …

Many biopharmaceuticals are now produced as secreted glycoproteins from mammalian cell
culture. The glycosylation profile of these proteins is essential to ensure structural stability …

Introduction: Glycans are increasingly important in the development of new
biopharmaceuticals with optimized efficacy, half-life, and antigenicity. Current expression …

Protein glycosylation, the enzymatic modification of amino acid sidechains with sugar
moieties, plays critical roles in cellular function, human health, and biotechnology. However …

Highlights•Non-human mammalian cells can produce immunogenic glycans.•Several
human cells are now available for production of biopharmaceuticals.•Functional …